Maternal aryl hydrocarbon receptor activation protects newborns against necrotizing enterocolitis
- PMID: 33589625
- PMCID: PMC7884836
- DOI: 10.1038/s41467-021-21356-4
Maternal aryl hydrocarbon receptor activation protects newborns against necrotizing enterocolitis
Abstract
Necrotizing enterocolitis (NEC) is a disease of premature infants characterized by acute intestinal necrosis. Current dogma suggests that NEC develops in response to post-natal dietary and bacterial factors, and so a potential role for in utero factors in NEC remains unexplored. We now show that during pregnancy, administration of a diet rich in the aryl hydrocarbon receptor (AHR) ligand indole-3-carbinole (I3C), or of breast milk, activates AHR and prevents NEC in newborn mice by reducing Toll-like receptor 4 (TLR4) signaling in the newborn gut. Protection from NEC requires activation of AHR in the intestinal epithelium which is reduced in mouse and human NEC, and is independent of leukocyte activation. Finally, we identify an AHR ligand ("A18") that limits TLR4 signaling in mouse and human intestine, and prevents NEC in mice when administered during pregnancy. In summary, AHR signaling is critical in NEC development, and maternally-delivered, AHR-based therapies may alleviate NEC.
Conflict of interest statement
D.J.H., P.W., C.P.S., and P.L. have filed a patent application for the use of AHR agonists in the prevention and treatment of NEC. The remaining authors declare no competing interests.
Figures
References
-
- Flahive, C., Schlegel, A. & Mezoff, E. A. Necrotizing enterocolitis: updates on morbidity and mortality outcomes. J. Pediatr.10.1016/j.jpeds.2019.12.035 (2020). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
